(Q34756587)

4 August 2017

title

High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial (English)

1 reference

4 August 2017

0 references

1 reference

1 reference

Andrew D J Pearson

1

1 reference

4 August 2017

C Ross Pinkerton

2

1 reference

4 August 2017

Ian J Lewis

3

1 reference

4 August 2017

John Imeson

4

1 reference

4 August 2017

Caroline Ellershaw

5

1 reference

4 August 2017

David Machin

6

1 reference

4 August 2017

European Neuroblastoma Study Group

7

1 reference

4 August 2017

Children's Cancer and Leukaemia Group (CCLG formerly United Kingdom Children's Cancer Study Group)

8

1 reference

4 August 2017

publication date

1 March 2008

1 reference

Lancet Oncology Commission

4 August 2017

published in

1 reference

4 August 2017

volume

9

1 reference

4 August 2017

issue

3

1 reference

4 August 2017

page(s)

247-256

1 reference

High dose melphalan in the treatment of advanced neuroblastoma: results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970069-X

7 January 2021

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970069-X

7 January 2021

Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970069-X

7 January 2021

Cyclophosphamide/doxorubicin vs. cisplatin/teniposide in the treatment of children older than 12 months of age with disseminated neuroblastoma: a Pediatric Oncology Group Randomized Phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970069-X

7 January 2021

Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970069-X

7 January 2021

Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970069-X

7 January 2021

LMCE3 treatment strategy: results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970069-X

7 January 2021

High-dose rapid schedule chemotherapy for disseminated neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970069-X

7 January 2021

OPEC/OJEC for stage 4 neuroblastoma in children over 1 year of age.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970069-X

7 January 2021

International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970069-X

7 January 2021

A randomized trial of 13-Cis retinoic acid in children with advanced neuroblastoma after high-dose therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970069-X

7 January 2021

Ototoxicity of high-dose cis-platinum in children.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970069-X

7 January 2021

Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. European Osteosarcoma Intergroup

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970069-X

7 January 2021

Induction chemotherapy in metastatic neuroblastoma--does dose influence response? A critical review of published data standards, options and recommendations (SOR) project of the National Federation of French Cancer Centres (FNCLCC).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970069-X

7 January 2021

Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970069-X

7 January 2021

Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970069-X

7 January 2021

High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970069-X

7 January 2021

Prohibitive toxicity of a dose-intense regime for metastatic neuroblastoma containing ifosfamide, doxorubicin and cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970069-X

7 January 2021

Best practice in assessing ototoxicity in children with cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970069-X

7 January 2021

Neuroblastoma and treatment-related myelodysplasia/leukemia: the Memorial Sloan-Kettering experience and a literature review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970069-X

7 January 2021

10.1016/S1470-2045(08)70069-X

Identifiers

DOI

1 reference

4 August 2017

1 reference